Zynerba Pharmaceuticals Inc. (ZYNE)
$1.30
$0.00 (0.00%)As on 13-Oct-2023 09:30EDT
Market cap
$70 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-19 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
53,939,400
10 Years Aggregate
CFO
$-224.74 Mln
EBITDA
$-272.24 Mln
Net Profit
$-268.43 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals (ZYNE)
| 145.3 | -1.5 | 286.8 | 90.9 | -28.9 | -29.1 | -- |
|
BSE Sensex*
| -12.9 | -5.3 | -6.6 | -10.3 | 5.3 | 7.1 | 10.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals (ZYNE)
| -81.6 | -12.7 | -45.4 | 103.4 | -76.1 | -19.7 | 54.8 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals (ZYNE)
|
1.3 | 70.1 | 0.0 | -37.0 | -- | -98.4 | -- | 0.5 |
| 0.7 | 5.0 | 2.0 | 17.2 | -618.4 | -- | -- | 7.5 |
Shareholding Pattern
View DetailsAbout Zynerba Pharmaceuticals (ZYNE)
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is... developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc. Read more
-
Chairman & CEO
Mr. Armando Anido MBA
-
Chairman & CEO
Mr. Armando Anido MBA
-
Headquarters
Devon, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Zynerba Pharmaceuticals (ZYNE)
What is the current share price of Zynerba Pharmaceuticals Inc (ZYNE) Today?
The share price of Zynerba Pharmaceuticals Inc (ZYNE) is $1.30 (NASDAQ) as of 13-Oct-2023 09:30 EDT. Zynerba Pharmaceuticals Inc (ZYNE) has given a return of -28.85% in the last 3 years.
What is the current PB & PE ratio of Zynerba Pharmaceuticals Inc (ZYNE)?
Since, TTM earnings of Zynerba Pharmaceuticals Inc (ZYNE) is negative, P/E ratio is not available.
The P/B ratio of Zynerba Pharmaceuticals Inc (ZYNE) is 0.54 times as on 08-Nov-2023, a 87 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.69
|
0.52
|
|
2021
|
-3.08
|
1.63
|
|
2020
|
-1.92
|
1.61
|
|
2019
|
-4.46
|
1.85
|
|
2018
|
-1.31
|
0.91
|
What is the 52 Week High and Low of Zynerba Pharmaceuticals Inc (ZYNE)?
The 52-week high and low of Zynerba Pharmaceuticals Inc (ZYNE) are Rs -- and Rs -- as of 08-Jun-2026.
What is the market cap of Zynerba Pharmaceuticals Inc (ZYNE)?
Zynerba Pharmaceuticals Inc (ZYNE) has a market capitalisation of $ 70 Mln as on 08-Nov-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Zynerba Pharmaceuticals Inc (ZYNE)?
Before investing in Zynerba Pharmaceuticals Inc (ZYNE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.